Inclusion Criteria:

- Patients must have histologically or cytologically confirmed malignant solid tumor.

- Patients who are amenable to standard combination chemotherapy of carboplatin and
paclitaxel.

- Patients should have received less than or equal to 1 prior chemotherapy regimens for
advanced stage disease.

- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.

- Patients must have normal organ and marrow function

Exclusion Criteria:

- Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for
nitrosoureas or mitomycin C) prior to entering the study or the adverse events due to
agents administered more than 3 weeks earlier have not recovered to less than grade
2.

- Known history of allergic reactions to carboplatin or cremophor-paclitaxel.

- Patients who have previously received a poly(ADP-ribose) polymerase (PARP) inhibitor.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
systemic infection requiring treatment, symptomatic congestive heart failure, angina
pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
limit compliance with study requirements.

- History of seizure disorder.

- Hepatitis B surface antigen (HBsAg) positive, Hepatitis C virus (HCV) antibody
positive or Human immunodeficiency virus (HIV)-positive patients.